NCCN GuidelinesVersion 2 . 2014 Myelodysplastic Syndromes Table of Contents

[1]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[2]  H. Baker.  Low-dose decitabine for myelodysplastic syndrome , 2013 .

[3]  Y. Miyazaki,et al.  [Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes]. , 2013, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[4]  P. Greenberg,et al.  A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine , 2013, Leukemia & lymphoma.

[5]  A. Glasmacher,et al.  Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis , 2012, Leukemia.

[6]  R. Larson,et al.  A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide , 2012, Journal of Hematology & Oncology.

[7]  M. Tormo,et al.  Identification of Poor Risk Patients in Low and Intermediate-1 (Int-1) IPSS MDS with the New Ipssr Index and Comparison with Other Prognostic Indexes. A Study by the Spanish Group of MDS (GESMD) , 2012 .

[8]  A. Stamatoullas,et al.  Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience , 2012 .

[9]  Pearlie K. Epling-Burnette,et al.  Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications. , 2012 .

[10]  J. Lancet,et al.  Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes , 2012 .

[11]  D. Mikulenková,et al.  A reclassification of Myelodysplastic Syndrome (MDS) patients of RAEB-1 subgroup according to IPSS-R improves discrimination of high risk patients and better predicts overall Survival. A retrospective analysis of 49 Patients , 2012 .

[12]  A. Levis,et al.  High Predictive Value of the Revised International Prognostic Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry , 2012 .

[13]  Jeffrey S. Miller,et al.  Comparison of IPSS and IPSS-R Scoring in a Population Based Myelodysplastic Syndromes (MDS) Study , 2012 .

[14]  A. Duhamel,et al.  Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Neuberg,et al.  Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Deeg,et al.  Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. , 2012, Blood.

[17]  C. Pascutto,et al.  Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study , 2012, Haematologica.

[18]  E. Estey,et al.  Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  D. Steensma,et al.  Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Michael Heuser,et al.  Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.

[21]  Claude Preudhomme,et al.  Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. , 2012, Blood.

[22]  C. Steidl,et al.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Órfão,et al.  Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group , 2012, Leukemia.

[24]  H. Kantarjian,et al.  Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes , 2011 .

[25]  J. Vardiman,et al.  Myelodysplastic/myeloproliferative neoplasms. , 2011, Seminars in diagnostic pathology.

[26]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[27]  C. Owen,et al.  Familial myelodysplastic syndromes: a review of the literature , 2011, Haematologica.

[28]  M. Cazzola,et al.  Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) , 2011, Haematologica.

[29]  R. Hawkins,et al.  Response, survival, and toxicity after iodine‐131–metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults , 2011, Cancer.

[30]  N. Young,et al.  Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. , 2011, The New England journal of medicine.

[31]  Anna L. Brown,et al.  Heritable GATA2 Mutations Associated with Familial Myelodysplastic Syndrome and Acute Myeloid Leukemia , 2011, Nature Genetics.

[32]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[33]  C. Schumann,et al.  Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  G. Mufti,et al.  Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes , 2011, Cancer.

[35]  M. Suarez‐Almazor,et al.  Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  F. Sigaux,et al.  Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. , 2011, Blood.

[37]  H. Papadaki,et al.  Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. , 2011, Leukemia research.

[38]  Yow-Ming C Wang,et al.  Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes , 2011, Cancer.

[39]  M. Loh,et al.  Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia , 2011, British journal of haematology.

[40]  C. Niemeyer,et al.  Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study , 2011, Leukemia.

[41]  Luca Malcovati,et al.  Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome , 2011, Haematologica.

[42]  Benjamin L Ebert,et al.  Unraveling the molecular pathophysiology of myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. Arceci.  Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors , 2011 .

[44]  P. Valent,et al.  Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical Features and Standard Evaluation , 2011 .

[45]  H. Deeg,et al.  Who is fit for allogeneic transplantation? , 2010, Blood.

[46]  Z. Cabantchik,et al.  Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. , 2010, Leukemia research.

[47]  N. Young,et al.  A Randomized Trial of Horse Versus Rabbit Antithymocyte Globulin In Severe Acquired Aplastic Anemia , 2010 .

[48]  J. Harbott,et al.  Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. , 2010, Blood.

[49]  E. Legius,et al.  Clinical and hematologic findings in Noonan syndrome patients with PTPN11 gene mutations , 2010, American journal of medical genetics. Part A.

[50]  J. Gabrilove,et al.  Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. , 2010, Blood.

[51]  A. Jafarzadeh,et al.  Immunological and hematological changes in patients with hyperthyroidism or hypothyroidism. , 2010, Clinical and investigative medicine. Medecine clinique et experimentale.

[52]  L. Medeiros,et al.  REVIEW: Recent advances in the diagnosis and classification of myeloid neoplasms – comments on the 2008 WHO classification , 2010, International journal of laboratory hematology.

[53]  A. Ganser,et al.  Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. , 2010, Leukemia research.

[54]  M. Ahluwalia,et al.  Multiparameter flow cytometry for the diagnosis and monitoring of small GPI‐deficient cellular populations , 2010, Cytometry. Part B, Clinical cytometry.

[55]  A. Baruchel,et al.  Myeloid leukaemia in children with down syndrome: Report of the registry‐based French experience between 1990 and 2003 , 2010, Pediatric blood & cancer.

[56]  P. Rosenberg,et al.  Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study , 2010, British journal of haematology.

[57]  F. Craig,et al.  Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry , 2010, Cytometry. Part B, Clinical cytometry.

[58]  J. Sierra,et al.  Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  J. Sierra,et al.  Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. , 2010, Blood.

[60]  J. Perkins,et al.  5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation , 2010, Bone Marrow Transplantation.

[61]  R. Larson,et al.  Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  I. Miron,et al.  [Diamond-Blackfan anemia. Case report]. , 2010, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi.

[63]  P. Valent,et al.  Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  M. Millenson,et al.  NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[65]  C. Gross,et al.  Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. , 2009, Leukemia research.

[66]  A. Stamatoullas,et al.  High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa (DAR) +/−G-CSF in Lower-Risk MDS : a Phase II Study. , 2009 .

[67]  D. Mikulenková,et al.  Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. , 2009, Leukemia research.

[68]  R. Claus,et al.  Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients , 2009, Bone Marrow Transplantation.

[69]  M. Kawahara,et al.  Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. , 2009, Blood.

[70]  D. Birnbaum,et al.  TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). , 2009, Blood.

[71]  R. Vij,et al.  A phase II study of 5‐day intravenous azacitidine in patients with myelodysplastic syndromes , 2009, American journal of hematology.

[72]  Wolfgang Kern,et al.  Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes , 2009, Haematologica.

[73]  U. Germing,et al.  The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome , 2009, Haematologica.

[74]  J. Hainsworth,et al.  Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  K. Welte,et al.  Severe congenital neutropenia. , 2009, Hematology/oncology clinics of North America.

[76]  L. Isola,et al.  The evolution of hematopoietic SCT in myelodysplastic syndrome , 2009, Bone Marrow Transplantation.

[77]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[78]  H. Deeg,et al.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[79]  J. Ivanovich,et al.  TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. , 2009, Blood.

[80]  C. Bloomfield,et al.  The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia : Rationale and Important Changes , 2009 .

[81]  B. Alter,et al.  Bone marrow cell cycle markers in inherited bone marrow failure syndromes. , 2008, Leukemia research.

[82]  J. Sierra,et al.  Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients with AML and MDS: Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) , 2008 .

[83]  M. Lübbert,et al.  Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups , 2008 .

[84]  M. Schmid,et al.  Efficacy and Safety of Deferasirox (Exjade ® ) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from EPIC Trial , 2008 .

[85]  J. Lazarchick,et al.  Pancytopenia with myelodysplasia due to copper deficiency , 2008, Pediatric blood & cancer.

[86]  Hee-Jin Kim,et al.  Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification‐Based Prognostic Scoring System (WPSS) and comparison with IPSS , 2008, European journal of haematology.

[87]  P. Greenberg,et al.  International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes , 2008, American journal of hematology.

[88]  C. Pascutto,et al.  WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). , 2008, Blood.

[89]  M. Cazzola,et al.  Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  H. Dombret,et al.  Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. , 2008, Leukemia research.

[91]  Y. Liu,et al.  [Characteristics of chronic active Epstein-Barr virus infection-associated hematological disorders in children]. , 2008, Zhongguo shi yan xue ye xue za zhi.

[92]  John Barrett,et al.  Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  N. Sayınalp,et al.  Copper deficiency with increased hematogones mimicking refractory anemia with excess blasts. , 2008, Leukemia research.

[94]  M. Maris,et al.  Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[95]  H. Dombret,et al.  Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. , 2008, Blood.

[96]  J. Maciejewski,et al.  Hypocupremia and bone marrow failure , 2008, Haematologica.

[97]  M. Gordon.  Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .

[98]  H. Kantarjian,et al.  A prognostic score for patients with lower risk myelodysplastic syndrome , 2008, Leukemia.

[99]  J. Reeves,et al.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. , 2008, Blood.

[100]  L. Malcovati.  Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. , 2007, Leukemia research.

[101]  H. Deeg,et al.  Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  B. Wood,et al.  Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia. , 2007, Clinics in laboratory medicine.

[103]  S. Chanock,et al.  Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. , 2007, Blood.

[104]  M. Cazzola,et al.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  T. Haferlach,et al.  Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. , 2007, Leukemia research.

[106]  S. Mayne,et al.  Myelodysplastic syndromes , 2007, Cancer.

[107]  A. Vincent,et al.  Hypocupremia associated with prior vitamin B12 deficiency , 2007, American journal of hematology.

[108]  J. Issa,et al.  Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome , 2007, Cancer.

[109]  J. Issa,et al.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.

[110]  C. Zwaan,et al.  Stem cell transplantation in pediatric leukemia and myelodysplasia: state of the art and current challenges. , 2007, Current stem cell research & therapy.

[111]  Bruce Greig,et al.  2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia , 2007, Cytometry. Part B, Clinical cytometry.

[112]  F. Askin,et al.  Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. , 2007, Blood.

[113]  J. Melo,et al.  Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. , 2007, Blood.

[114]  J. Maciejewski,et al.  Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. , 2006, Blood.

[115]  R. Larson,et al.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[117]  L. Mannone,et al.  High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study , 2006, British journal of haematology.

[118]  S. Nimer,et al.  Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[120]  T. Vulliamy,et al.  Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. , 2006, Blood.

[121]  Jun Wang,et al.  5q- Syndrome in a Child With Slowly Progressive Pancytopenia: A Case Report and Review of the Literature , 2006, Journal of pediatric hematology/oncology.

[122]  U. Germing,et al.  Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals , 2006, British journal of haematology.

[123]  M. Gordon.  Efficacy of Lenalidomide in Myelodysplastic Syndromes , 2006 .

[124]  M. Tormo,et al.  Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. , 2006, Cancer.

[125]  P. Greenberg.  Myelodysplastic syndromes: iron overload consequences and current chelating therapies. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[126]  H. Deeg,et al.  Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis , 2006, Leukemia.

[127]  J. Ford,et al.  Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. , 2006, Haematologica.

[128]  U. Germing,et al.  Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. , 2006, Haematologica.

[129]  J. Schulte‐Mönting,et al.  Comparison of five prognostic scoring systems, the French–American–British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis , 2006, Annals of Hematology.

[130]  S. Amadori,et al.  Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[131]  M. Lübbert,et al.  Response Rates of Phase 2 and Phase 3 Trials of Decitabine (DAC) in Patients with Myelodysplastic Syndromes (MDS). , 2005 .

[132]  P. Greenberg,et al.  Management of patients with higher risk myelodysplastic syndromes. , 2005, Critical reviews in oncology/hematology.

[133]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  H. Deeg,et al.  Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[135]  B. Zhivotovsky,et al.  Antiapoptotic Role of Growth Factors in the Myelodysplastic Syndromes: Concordance Between In vitro and In vivo Observations , 2005, Clinical Cancer Research.

[136]  David P Steensma,et al.  The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. , 2005, Blood.

[137]  Y. Li,et al.  Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. , 2005, American journal of clinical pathology.

[138]  H. Deeg,et al.  Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[140]  F. Lanza,et al.  Darbepoetin alpha for the treatment of anaemia in low‐intermediate risk myelodysplastic syndromes , 2005, British journal of haematology.

[141]  E. Vellenga,et al.  Studies on megakaryopoiesis in patients with myelodysplasia and idiopathic thrombocytopenic purpura , 2008 .

[142]  J. Gribben,et al.  Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. , 2004, Blood.

[143]  S. Hunger,et al.  Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT) , 2005, Bone Marrow Transplantation.

[144]  H. Deeg.  Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS). , 2005, Hematology. American Society of Hematology. Education Program.

[145]  R. Latagliata,et al.  Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome , 2005, Annals of Hematology.

[146]  J. Issa,et al.  First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS). , 2004 .

[147]  H. Deeg,et al.  Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. , 2004, Leukemia research.

[148]  M. Lübbert,et al.  The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. , 2004, Leukemia research.

[149]  M. Munsell,et al.  Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[150]  H. Dombret,et al.  Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. , 2004, Blood.

[151]  John P Klein,et al.  A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. , 2004, Blood.

[152]  R. Advani,et al.  Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  H. Heimpel,et al.  A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes , 2004, Leukemia.

[154]  R. Ware,et al.  Acute parvovirus B19 infection mimicking congenital dyserythropoietic anemia. , 2004, Journal of pediatric hematology/oncology.

[155]  J. Harbott,et al.  Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. , 2003, Blood.

[156]  R. Hawkins,et al.  Secondary Myelodysplastic Syndrome and Leukemia Following 131I-Metaiodobenzylguanidine Therapy for Relapsed Neuroblastoma , 2003, Journal of pediatric hematology/oncology.

[157]  H. Deeg,et al.  Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. , 2003, Blood.

[158]  C. Stiller,et al.  Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population‐based study of incidence and survival , 2003, British journal of haematology.

[159]  H. Eiskjaer,et al.  Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. , 2003, Blood.

[160]  E. Neufeld,et al.  Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial , 2003, The Lancet.

[161]  D. Bowen,et al.  Oxidative Stress and the Myelodysplastic Syndromes , 2003, International journal of hematology.

[162]  J. Cayuela,et al.  Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  I. Dybedal,et al.  A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life , 2003, British journal of haematology.

[164]  S. Kulkarni,et al.  Novel translocations that disrupt the platelet‐derived growth factor receptor β (PDGFRB) gene in BCR–ABL‐negative chronic myeloproliferative disorders , 2003, British journal of haematology.

[165]  F. Jensen,et al.  Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. , 2003, Blood.

[166]  G. Brittenham,et al.  Noninvasive measurement of iron: report of an NIDDK workshop. , 2003, Blood.

[167]  M. Mori,et al.  Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. , 2002, Blood.

[168]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[169]  N. Young,et al.  HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. , 2002, Blood.

[170]  J. Prchal,et al.  Copper deficiency masquerading as myelodysplastic syndrome. , 2002, Blood.

[171]  S. Cheong,et al.  GATA-1 and GATA-2 gene expression is related to the severity of dysplasia in myelodysplastic syndrome , 2002, Leukemia.

[172]  Yu Shen,et al.  Myelodysplastic syndrome is not merely "preleukemia". , 2002, Blood.

[173]  M. K. Magnússon,et al.  Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. , 2002, Blood.

[174]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[175]  J. Holland,et al.  Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  K. Welte,et al.  Kostmann syndrome and severe congenital neutropenia. , 2002, Seminars in hematology.

[177]  H. Deeg,et al.  Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. , 2002, Blood.

[178]  N. Cross,et al.  Myeloproliferative Disorders with Translocations of Chromosome 5q31–35: Role of the Platelet-Derived Growth Factor Receptor Beta , 2002, Acta Haematologica.

[179]  H. Deeg,et al.  Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[180]  Yoshiaki Ito,et al.  In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. , 2002, Blood.

[181]  H. Deeg,et al.  Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study , 2002, Leukemia.

[182]  U. Germing,et al.  Thalidomide for the treatment of patients with myelodysplastic syndromes , 2002, Leukemia.

[183]  Duardo,et al.  RESPONSE TO IMATINIB MESYLATE IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISEASES WITH REARRANGEMENTS OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA , 2002 .

[184]  P. Thall,et al.  Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. , 2001, Blood.

[185]  M. Taniwaki,et al.  International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome , 2001, British journal of haematology.

[186]  E. Estey,et al.  High‐dose chemotherapy in high‐risk myelodysplastic syndrome , 2001, Cancer.

[187]  A. Hagemeijer,et al.  Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. , 2001, Blood.

[188]  P. Venugopal,et al.  Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. , 2001, Blood.

[189]  M. Lübbert,et al.  Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine , 2001, British journal of haematology.

[190]  U. Germing,et al.  Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. , 2000, Leukemia research.

[191]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[192]  D. Head.  Problematic WHO Reclassification of Myelodysplastic Syndromes , 2000 .

[193]  D. Uçkan,et al.  Acute parvovirus B19 infection mimicking juvenile myelomonocytic leukemia , 2000, European journal of haematology.

[194]  Y. Aizawa,et al.  Thrombopoietin activates the growth of megakaryoblasts in patients withchronic myeloproliferative disorders and myelodysplastic syndrome , 2000, European journal of haematology.

[195]  B. Alter,et al.  Fanconi anemia: myelodysplasia as a predictor of outcome. , 2000, Cancer genetics and cytogenetics.

[196]  M. Lübbert,et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[197]  K. Dan,et al.  Effect of Thrombopoietin on Proliferation of Blasts from Patients with Myelodysplastic Syndromes , 2000, Stem cells.

[198]  A. Nademanee,et al.  Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. , 2000, Blood.

[199]  G Flandrin,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.

[201]  N. Young,et al.  Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure Syndromes , 1999, Annals of Internal Medicine.

[202]  R. Advani,et al.  Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar) , 1999 .

[203]  E. Solary,et al.  Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS. , 1999, Advances in experimental medicine and biology.

[204]  Dan,et al.  Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes , 1998, British journal of haematology.

[205]  E. Estey,et al.  NCCN practice guidelines for the myelodysplastic syndromes , 1998 .

[206]  C. Felix.  Secondary leukemias induced by topoisomerase-targeted drugs. , 1998, Biochimica et biophysica acta.

[207]  D. Horsman,et al.  Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. , 1998, Blood.

[208]  I. Dybedal,et al.  Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. , 1998, Blood.

[209]  G. Link,et al.  Pathophysiology of Iron Overload a , 1998, Annals of the New York Academy of Sciences.

[210]  M. Gallego,et al.  Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy. , 1998, Leukemia research.

[211]  W. Roberts,et al.  Bone marrow transplantation in Shwachman–Diamond syndrome: report of two cases and review of the literature , 1998, Bone Marrow Transplantation.

[212]  H. Zwierzina,et al.  Endogenous serum thrombopoietin concentrations in patients with myelodysplastic syndromes , 1998, Leukemia.

[213]  P. Greenberg,et al.  Prognostic factors and scoring systems in myelodysplastic syndromes. , 1998, Haematologica.

[214]  N. Young,et al.  Antithymocyte globulin for patients with myelodysplastic syndrome , 1997, British journal of haematology.

[215]  P. Greenberg,et al.  Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model , 1997, British journal of haematology.

[216]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[217]  J. Čermák,et al.  164 Promising cyclosporin a therapy for myelodysplastic syndrome , 1997 .

[218]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[219]  J. Harbott,et al.  Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. , 1996, Leukemia.

[220]  B. Alter.  Fanconi's anemia and malignancies , 1996, American journal of hematology.

[221]  F. Jensen,et al.  The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload , 1996, British journal of haematology.

[222]  P. Greenberg,et al.  Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. , 1996, Blood.

[223]  H. van den Berghe,et al.  Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. , 1996, Bone marrow transplantation.

[224]  J. Bennett,et al.  Morphology and classification of the myelodysplastic syndromes and their pathologic variants. , 1996, Seminars in hematology.

[225]  K. Sullivan,et al.  Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS‐related acute myeloid leukaemia , 1996, British journal of haematology.

[226]  H. Hasle,et al.  Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. , 1995, Leukemia.

[227]  N. Ellison.  Hematology, Basic Principles and Practice, 2nd ed , 1995 .

[228]  E. Hellström-Lindberg.  Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studies , 1995, British journal of haematology.

[229]  H. Hasle,et al.  Myelodysplastic syndrome in a child with constitutional trisomy 8 mosaicism and normal phenotype. , 1995, Cancer genetics and cytogenetics.

[230]  H. Gralnick,et al.  The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group , 1994, British journal of haematology.

[231]  R. Ware,et al.  Mutations within the Piga gene in patients with paroxysmal nocturnal hemoglobinuria. , 1994, Blood.

[232]  A. Zipursky,et al.  Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. , 1994, Leukemia research.

[233]  A. Georgii,et al.  Comparison of bone marrow and hematologic findings in patients with human immunodeficiency virus infection and those with myelodysplastic syndromes and infectious diseases. , 1994, American journal of clinical pathology.

[234]  F. Appelbaum,et al.  Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. , 1993, Blood.

[235]  P. Sonneveld,et al.  High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. , 1993, Leukemia.

[236]  Teizo Fujita,et al.  Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria , 1993, Cell.

[237]  G. Jackson,et al.  Myelodysplastic syndromes in children. , 1993, British journal of haematology.

[238]  A. Zipursky,et al.  Leukemia in Down syndrome: a review. , 1992, Pediatric hematology and oncology.

[239]  U. Germing,et al.  [Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes]. , 1992, Beitrage zur Infusionstherapie = Contributions to infusion therapy.

[240]  P. Greenberg.  Treatment of myelodysplastic syndromes. , 1991, Blood reviews.

[241]  S. Toledano,et al.  Monosomy 7 syndrome. Clinical heterogeneity in children and adolescents. , 1990, Cancer genetics and cytogenetics.

[242]  A. Gratwohl,et al.  Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG) , 1990, British journal of haematology.

[243]  J. Caro,et al.  Circulating erythropoietin in patients with myelodysplastic syndromes , 1989, British journal of haematology.

[244]  G. Tricot,et al.  The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes , 1986, British journal of haematology.

[245]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[246]  R. Gleason,et al.  Clinical consequences of acquired transfusional iron overload in adults. , 1981, The New England journal of medicine.

[247]  T. D. Hamilton,et al.  Classification of Tumours , 1930, Edinburgh medical journal.